These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 4440578)

  • 1. Dihydroxyphenylacetic acid in the treatment of Parkinsonism.
    Ericsson AD; McCann DS
    Adv Neurol; 1974; 5():301-6. PubMed ID: 4440578
    [No Abstract]   [Full Text] [Related]  

  • 2. The "on-off" side effect of L-DOPA.
    Markham CH
    Adv Neurol; 1974; 5():387-96. PubMed ID: 4440586
    [No Abstract]   [Full Text] [Related]  

  • 3. Piribedil in Parkinsonism.
    Cane DB
    Adv Neurol; 1974; 5():325. PubMed ID: 4613159
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
    Youdim MB
    Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 7. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.
    Kurkela M; Siiskonen A; Finel M; Tammela P; Taskinen J; Vuorela P
    Anal Biochem; 2004 Aug; 331(1):198-200. PubMed ID: 15246016
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinsonism and its treatment.
    Strouthidis TM
    Nurs Mirror Midwives J; 1974 Sep; 139(12):44-8. PubMed ID: 4610518
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations in the "on-off" phenomenon.
    Duvoisin RC
    Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of Parkinson's disease with COMT inhibitors].
    Shabtai H; Korczyn A
    Harefuah; 2001 Oct; 140(10):935-7. PubMed ID: 11681127
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture risk associated with parkinsonism and anti-Parkinson drugs.
    Vestergaard P; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2007 Sep; 81(3):153-61. PubMed ID: 17705047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term approaches to the "on-off" phenomenon.
    Papavasiliou PS; Cotzias GC; Mena I
    Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-stage parkinsonism with mild motor fluctuations.
    Tolosa E; Valldeoriola F
    Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
    Reilly DK; Hershey L; Rivera-Calimlim L; Shoulson I
    Adv Neurol; 1983; 37():51-60. PubMed ID: 6344591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
    Namba S; Ishimitsu H; Nakasone S
    No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
    [No Abstract]   [Full Text] [Related]  

  • 20. Tardive syndrome and Parkinson's disease responsive to concomitant tetrabenazine and levodopa therapy.
    Kurtis MM; Franch O
    Parkinsonism Relat Disord; 2011 Dec; 17(10):774-6. PubMed ID: 21733737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.